Compare OOMA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | SGHT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 187.4M |
| IPO Year | 2015 | 2021 |
| Metric | OOMA | SGHT |
|---|---|---|
| Price | $14.67 | $3.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $18.77 | $9.08 |
| AVG Volume (30 Days) | 268.4K | ★ 356.1K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $114,490,000.00 | $77,363,000.00 |
| Revenue This Year | $20.35 | $11.67 |
| Revenue Next Year | $3.82 | $10.39 |
| P/E Ratio | $163.44 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $2.03 |
| 52 Week High | $15.15 | $9.24 |
| Indicator | OOMA | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 35.68 |
| Support Level | $10.95 | $3.29 |
| Resistance Level | $14.83 | $3.76 |
| Average True Range (ATR) | 0.48 | 0.22 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 74.71 | 15.71 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.